An anonymous reader quotes a report from Ars Technica: Over the nine or so years that Mylan, Inc. has been selling -- and hiking the price -- of EpiPens, the drug company has been misclassifying the life-saving device and stiffing Medicaid out of full rebate payments, federal regulators told Ars. Under the Medicaid Drug Rebate Program, drug manufacturers, such as Mylan, can get their products covered by Medicaid if they agree to offer rebates to the government to offset costs. With a brand-name drug such as the EpiPen, which currently has no generic versions and has patent protection, Mylan was supposed to classify the drug as a "single source," or brand name drug. That would mean Mylan is required to offer Medicaid a rebate of 23.1 percent of the costs, plus an "inflation rebate" any time Mylan raises the price of the brand-name drug at a rate higher than inflation. Mylan has opted for such price increases -- a lot. Since Mylan bought the rights to EpiPen in 2007, it has raised the price on 15 separate occasions, bringing the current list price to $608 for a two-pack up from about $50 a pen in 2007. That's an increase of more than 500 percent, which easily beats inflation. But instead of classifying EpiPen as a "single source" drug, Mylan told regulators that it's a "non-innovator multiple source," or generic drug. Under that classification, Mylan is only required to offer a rebate of 13 percent and no inflation rebates. It's unclear how much money Mylan has skipped out on paying in total to state and federal governments. But according to the state health department of Minnesota, as reported by CNBC, the misclassification cost that state $4.3 million this year alone.pdiv class="share_submission" style="position:relative;"
a class="slashpop" href="http://twitter.com/home?status=Feds+Go+After+Mylan+For+Scamming+Medicaid+Out+of+Millions+On+EpiPen+Pricing%3A+http%3A%2F%2Fbit.ly%2F2dGBBfy"img src="https://a.fsdn.com/sd/twitter_icon_large.png"/a
a class="slashpop" href="http://www.facebook.com/sharer.php?u=https%3A%2F%2Fyro.slashdot.org%2Fstory%2F16%2F09%2F30%2F212212%2Ffeds-go-after-mylan-for-scamming-medicaid-out-of-millions-on-epipen-pricing%3Futm_source%3Dslashdot%26utm_medium%3Dfacebook"img src="https://a.fsdn.com/sd/facebook_icon_large.png"/a
a class="nobg" href="http://plus.google.com/share?url=https://yro.slashdot.org/story/16/09/30/212212/feds-go-after-mylan-for-scamming-medicaid-out-of-millions-on-epipen-pricing?utm_source=slashdotamp;utm_medium=googleplus" onclick="javascript:window.open(this.href,'', 'menubar=no,toolbar=no,resizable=yes,scrollbars=yes,height=600,width=600');return false;"img src="http://www.gstatic.com/images/icons/gplus-16.png" alt="Share on Google+"//a
/div/ppa href="https://yro.slashdot.org/story/16/09/30/212212/feds-go-after-mylan-for-scamming-medicaid-out-of-millions-on-epipen-pricing?utm_source=rss1.0moreanonamp;utm_medium=feed"Read more of this story/a at Slashdot./pimg src="http://feeds.feedburner.com/~r/Slashdot/slashdotScience/~4/drNIDG9goEU" height="1" width="1" alt=""/
